Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;4(4):219-26.
doi: 10.1177/1756283X11398735.

Proton-pump inhibitors for the treatment of functional dyspepsia

Hidekazu Suzuki  1 , Sawako Okada, Toshifumi Hibi
Affiliations

Proton-pump inhibitors for the treatment of functional dyspepsia

Hidekazu Suzuki et al. Therap Adv Gastroenterol. 2011 Jul.

Abstract

In the Rome III classification, functional dyspepsia (FD) has been further subcategorized into two different syndromes, namely, epigastric pain syndrome (EPS) and postprandial distress syndrome (PDS). Acid-related pathophysiology seems to be mainly responsible for EPS, and antisecretory agents such as proton-pump inhibitors (PPIs) seem to be effective mainly against EPS. However, recent information as to the relationship between initial duodenal acid sensitization in the early postprandial phase and delayed gastric emptying in the later postprandial phase would suggest the amelioration of PDS by antisecretory agents. In the present review, we summarized the recent literature on the direct and indirect effect of PPIs in FD (including not only Rome III, but also Rome II criteria). The effects of PPIs against FD are heterogeneous, depending on the protocol of the clinical studies, and the inclusion criteria of each randomized controlled trial (primary care or tertiary care population). As the placebo effects cannot be ignored in this disease, a placebo-controlled study would be necessary, at least for the evaluation of the effect of each agent on symptom relief in patients with FD. Further studies directly comparing PPIs with suitable placebos in terms of their effects in reducing the symptoms of endoscopically confirmed, Rome III-based FD are awaited.

Keywords: Helicobacter pylori; antisecretory agents; functional gastrointestinal disorders; randomized controlled study; uninvestigated dyspepsia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Literature selection flow. DB, database; FD, functional dyspepsia; PPI, proton-pump inhibitor.
See this image and copyright information in PMC

References

    1. Bolling-Sternevald E., Lauritsen K., Talley N.J., Junghard O., Glise H. (2003) Is it possible to predict treatment response to a proton pump inhibitor in functional dyspepsia? Aliment Pharmacol Ther 18: 117–124 - PubMed
    1. Chiba N., Thomson A.B., Sinclair P. (2000) From bench to bedside to bug: an update of clinically relevant advances in the care of persons with Helicobacter pylori-associated diseases. Can J Gastroenterol 14: 188–198 - PubMed
    1. Ghosh A., Halder S., Mandal S., Mandal A., Basu M., Dabholkar P. (2008) Rabeto plus: a valuable drug for managing functional dyspepsia. J Indian Med Assoc 106: 752–754 - PubMed
    1. Grudell A.B., Camilleri M., Burton D.D., Stephens D.A. (2006) Effect of a proton pump inhibitor on postprandial gastric volume, emptying and symptoms in healthy human subjects: a pilot study. Aliment Pharmacol Ther 24: 1037–1043 - PubMed
    1. Kleibeuker J.H., Thijs J.C. (2004) Functional dyspepsia. Curr Opin Gastroenterol 20: 546–550 - PubMed